Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: A multicenter phase II study

Journal of Clinical Oncology

Volumn 30, Issue 8, 2012, Pages 837-842

  Ishida, Takashi ^a   Joh, Tatsuro ^d   Uike, Naokuni ^e   Yamamoto, Kazuhito ^b   Utsunomiya, Atae ^h   Yoshida, Shinichiro ^d   Saburi, Yoshio ⁱ   Miyamoto, Toshihiro ^f   Takemoto, Shigeki ^j   Suzushima, Hitoshi ^k   Tsukasaki, Kunihiro ^d   Nosaka, Kisato ^l   Fujiwara, Hiroshi ^m   Ishitsuka, Kenji ^g   Inagaki, Hiroshi ^a   Ogura, Michinori ^c   Akinaga, Shiro ⁿ   Tomonaga, Masao ^d   Tobinai, Kensei ^o   Ueda, Ryuzo ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

^c NAGOYA DAINI RED CROSS HOSPITAL   (Japan)

^d NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^e NATIONAL KYUSHU CANCER CENTER   (Japan)

^f KYUSHU UNIVERSITY   (Japan)

^g FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h IMAMURA BUN IN HOSPITAL   (Japan)

ⁱ OITA PREFECTURAL HOSPITAL   (Japan)

^j NATIONAL HOSPITAL ORGANIZATION KUMAMOTO MEDICAL CENTER   (Japan)

^k NTT West Japan Kyushu Hospital   (Japan)

^l KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

^m EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁿ KYOWA HAKKO KOGYO CO LTD   (Japan)

^o NATIONAL CANCER CENTER HOSPITAL   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR4; MOGAMULIZUMAB;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER RELAPSE; CHILL; CLINICAL ARTICLE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; ERYTHEMA MULTIFORME; FEMALE; FEVER; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; HYPERCALCEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPERURICEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTENSION; HYPOXEMIA; INJECTION SITE REACTION; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; METABOLIC DISORDER; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PRURITUS; RASH; SIDE EFFECT; T CELL LEUKEMIA; TACHYCARDIA; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME; WEIGHT GAIN;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LEUKEMIA-LYMPHOMA, ADULT T-CELL; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; RECURRENCE; T-LYMPHOCYTE SUBSETS; TREATMENT OUTCOME;

EID: 84863393084     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.37.3472     Document Type: Article

References (38)

1. Shimoyama M: Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma: A report from the Lymphoma Study Group (1984-87). Br J Haematol 79:428-437, 1991
2. Vose J, Armitage J, Weisenburger D: International peripheral T-cell and natural killer/T-cell lymphoma study: Pathology findings and clinical outcomes. J Clin Oncol 26:4124-4130, 2008
3. Uchiyama T, Yodoi J, Sagawa K, et al: Adult T-cell leukemia: Clinical and hematologic features of 16 cases. Blood 50:481-492, 1977 (Pubitemid 8180432)
4. Tsukasaki K, Hermine O, Bazarbachi A, et al: Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: A proposal from an international consensus meeting. J Clin Oncol 27:453-459, 2009
5. Tsukasaki K, Utsunomiya A, Fukuda H, et al: VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol 25:5458-5464, 2007 (Pubitemid 350232223)
6. Utsunomiya A, Miyazaki Y, Takatsuka Y, et al: Improved outcome of adult T cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 27:15-20, 2001 (Pubitemid 32124402)
7. Hishizawa M, Kanda J, Utsunomiya A, et al: Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: A nationwide retrospective study. Blood 116:1369-1376, 2010
8. Ishida T, Utsunomiya A, Iida S, et al: Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: Its close association with skin involvement and unfavorable outcome. Clin Cancer Res 9:3625-3634, 2003 (Pubitemid 37169227)
9. Yoshie O, Fujisawa R, Nakayama T, et al: Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T cells. Blood 99:1505-1511, 2002 (Pubitemid 34533017)
10. Shinkawa T, Nakamura K, Yamane N, et al: The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 278:3466-3473, 2003 (Pubitemid 36801263)
11. Ishii T, Ishida T, Utsunomiya A, et al: Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma. Clin Cancer Res 16:1520-1531, 2010
12. Ishida T, Iida S, Akatsuka Y, et al: The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-cell leukemia/lymphoma. Clin Cancer Res 10:7529-7539, 2004 (Pubitemid 39557514)
13. Ito A, Ishida T, Utsunomiya A, et al: Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2R gamma(null) mice in vivo. J Immunol 183: 4782-4791, 2009
14. Yamamoto K, Utsunomiya A, Tobinai K, et al: Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol 28:1591-1598, 2010
15. Tobinai K: Current management of adult T-cell leukemia/lymphoma. Oncology (Williston Park) 14: 1250-1256, 2009
16. Tobinai K, Uike N, Saburi Y, et al: Phase II study of cladribine (2-chlorodeoxyadenosine) in relapsed or refractory adult T-cell leukemia-lymphoma. Int J Hematol 77:512-517, 2003 (Pubitemid 36828316)
17. Tsuda H, Takatsuki K, Ohno R, et al: Treatment of adult T-cell leukaemia-lymphoma with irinotecan hydrochloride (CPT-11): CPT-11 Study Group on Hematological Malignancy. Br J Cancer 70:771-774, 1994 (Pubitemid 24305620)
18. Bazarbachi A, Plumelle Y, Carlos Ramos J, et al: Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol 28:4177-4183, 2010
19. Gill PS, Harrington W Jr, Kaplan MH, et al: Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med 332:1744-1748, 1995
20. White JD, Wharfe G, Stewart DM, et al: The combination of zidovudine and interferon alpha-2B in the treatment of adult T-cell leukemia/lymphoma. Leuk Lymphoma 40:287-294, 2001 (Pubitemid 32401385)
21. van der Kolk LE, Grillo-López AJ, Baars JW, et al: Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol 115:807-811, 2001 (Pubitemid 34042897)
22. Niwa R, Sakurada M, Kobayashi Y, et al: Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density. Clin Cancer Res 11:2327-2336, 2005 (Pubitemid 40490194)
23. Imai T, Nagira M, Takagi S, et al: Selective recruitment of CCR4-bearing Th2 cells toward antigen-presenting cells by the CC chemokines thymus and activation-regulated chemokine and macrophage-derived chemokine. Int Immunol 11: 81-88, 1999 (Pubitemid 29037591)
24. Iellem A, Mariani M, Lang R, et al: Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells. J Exp Med 194: 847-853, 2001 (Pubitemid 32983019)
25. Yagi H, Nomura T, Nakamura K, et al: Crucial role of FOXP3 in the development and function of human CD25+CD4+ regulatory T cells. Int Immunol 16:1643-1656, 2004
26. Ishida T, Ueda R: CCR4 as a novel molecular target for immunotherapy of cancer. Cancer Sci 97:1139-1146, 2006 (Pubitemid 44430638)
27. Ishida T, Ueda R: Immunopathogenesis of lymphoma: Focus on CCR4. Cancer Sci 102:44-50, 2011
28. Karube K, Ohshima K, Tsuchiya T, et al: Expression of FoxP3, a key molecule in CD4CD25 regulatory T cells, in adult T-cell leukaemia/lymphoma cells. Br J Hematol 126:81-84, 2004 (Pubitemid 38859486)
29. Yano H, Ishida T, Inagaki A, et al: Regulatory T-cell function of adult T-cell leukemia/lymphoma cells. Int J Cancer 120:2052-2057, 2007 (Pubitemid 46418388)
30. Hodi FS, O'Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723, 2010
31. + regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 192:303-310, 2000
32. Zou W: Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6:295-307, 2006
33. O'Day SJ, Hamid O, Urba WJ: Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): A novel strategy for the treatment of melanoma and other malignancies. Cancer 110:2614-2627, 2007 (Pubitemid 350250330)
34. Campbell JJ, Haraldsen G, Pan J, et al: The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells. Nature 400:776-780, 1999 (Pubitemid 29399540)
35. Ishida T, Inagaki H, Utsunomiya A, et al: CXCR3 and CCR4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified. Clin Cancer Res 10:5494-5500, 2004 (Pubitemid 39100487)
36. Weisenburger DD, Savage KJ, Harris NL, et al: Peripheral T-cell lymphoma, not otherwise specified: A report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood 117: 3402-3408, 2011
37. Duvic M, Pinter-Brown L, Foss FM, et al: Results of a phase 1/2 study for KW-0761, a monoclonal antibody directed against CC chemokine receptor type 4 (CCR4), in CTCL patients. Blood 116, 2010 (abstr 962)
38. Ishida T, Ishii T, Inagaki A, et al: Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. Cancer Res 66:5716-5722, 2006 (Pubitemid 43927124)